Back to Research Hub
Belite Bio, Inc
BLTE
$157.14-3.94 (-2.45%)
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease.
StreetsValue research for Belite Bio, Inc (BLTE)
Members get the full report for Belite Bio, Inc: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.